DexCom, Inc. (NASDAQ:DXCM) has shown a modest gain of 1.16% over the past 30 days, indicating positive investor sentiment.The company's projected growth potential of 22.52% underscores its promising future in the medical device industry.With a Piotroski Score of 8, DexCom demonstrates strong financial health, making it an attractive option for long-term investors.DexCom, Inc. (NASDAQ:DXCM) is a prominent player in the medical device industry, specializing in continuous glucose monitoring (CGM) systems for d ...

Key Takeaways DXCM beat Q4 EPS estimates as revenues rose 13% to $1.26B on strong U.S. and international demand.The nationwide G7 15 Day launch aims to set a new standard for customer experience.DXCM reaffirmed the 2026 revenue view of $5.16-$5.25B, projecting 11-13% growth.DexCom, Inc. (DXCM) reported fourth-quarter 2025 adjusted earnings per share (EPS) of 68 cents, which beat the Zacks Consensus Estimate of 65 cents by 4.6%. The company reported adjusted earnings of 45 cents per share in the prior-year q ...

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

DexCom (DXCM) came out with quarterly earnings of $0.68 per share, beating the Zacks Consensus Estimate of $0.65 per share. This compares to earnings of $0.45 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +4.62%. A quarter ago, it was expected that this medical device company would post earnings of $0.57 per share when it actually produced earnings of $0.61, delivering a surprise of +7.02%.Over the last four quarters, the co ...

Here's a look at the details in the report. Watch the price DXCM action here.The Details: DexCom reported quarterly earnings of 68 cents per share, which beat the Street estimate of 65 cents, according to data from Benzinga Pro.Quarterly revenue came in at $1.26 billion, which beat the analyst estimate of $1.25 billion.U.S. revenue grew 11% and international revenue grew 18% on a reported basis, all on a year-over-year basis.Outlook: DexCom affirmed its fiscal 2026 revenue outlook for a range of $5.16 billi ...

Dexcom (NasdaqGS:DXCM) Q4 2025 Earnings call February 12, 2026 04:30 PM ET Company ParticipantsDavid Roman - Managing DirectorJake Leach - President and CEOJereme Sylvain - CFOJoanne Wuensch - Managing DirectorJosh Jennings - Managing DirectorMarie Thibault - Managing DirectorMatt Taylor - Managing DirectorRichard Newitter - Managing DirectorSean Christensen - VP of Finance and Investor RelationsTravis Steed - Managing DirectorZachary Day - Equity Research AssociateConference Call ParticipantsBrandon Vazque ...

Dexcom (NasdaqGS:DXCM) Q4 2025 Earnings call February 12, 2026 04:30 PM ET Company ParticipantsDavid Roman - Managing DirectorJake Leach - President and CEOJereme Sylvain - CFOJoanne Wuensch - Managing DirectorJosh Jennings - Managing DirectorMarie Thibault - Managing DirectorMatt Taylor - Managing DirectorRichard Newitter - Managing DirectorSean Christensen - VP of Finance and Investor RelationsTravis Steed - Managing DirectorZachary Day - Equity Research AssociateConference Call ParticipantsBrandon Vazque ...

Dexcom (NasdaqGS:DXCM) Q4 2025 Earnings call February 12, 2026 04:30 PM ET Speaker14Ladies and gentlemen, good afternoon, and welcome to the Dexcom fourth quarter and fiscal year 2025 earnings release conference call. My name is Abby, and I will be your operator today. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session. During the question-and-answer session, if you have a question, please press star one on your touchtone phone. As a reminder, the ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 000-51222 DEXCOM, INC. (Exact name of registrant as specified in its charter) Delaware 33-0857544 (State or other jurisdiction of incorporation or o ...

Dexcom earnings Q4 2025 Safe harbor statement This presentation contains "forward - looking statements" that are based on our management's beliefs and assumptions and on inform ation available to management as of February 12, 2026. We intend for such forward - looking statements to be covered by the safe harbor provisions fo r forward - looking statements contained in the U.S. Private Securities Litigation Reform Act of 1995. Forward - looking statements include informatio n concerning our possible or assum ...